Latest news with #Ahlen
Yahoo
23-04-2025
- Business
- Yahoo
Is NVIDIA (NVDA) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of . In this article, we are going to take a look at where NVIDIA Corporation (NASDAQ:NVDA) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over President Trump's tariffs earlier this month, but the rollercoaster is not over just yet. All three major indexes closed last week in the red, with the Dow and NASDAQ both dipping over 2%, and the broader market down more than 1%. Even though markets remain closed on April 18 for Good Friday, the general consensus is that the worst of the trade war headlines might be dying down. Marko Papic, chief strategist of geomacro strategy at BCA Research, remains cautiously optimistic, noting that while the idea of President Trump striking 90 trade deals in 90 days sounds ambitious, they will likely be small, symbolic wins that still help calm markets. That said, volatility is expected to continue, and Papic predicts the broader market could dip again before bouncing back, potentially giving investors a buying opportunity. Investors are deep in earnings season right now, and some of Wall Street's biggest banks have reported solid first-quarter results. A big part of their success came from their trading desks, which cashed in on the recent market volatility, especially in equities. However, despite strong numbers on paper, bank CEOs remain cautious and are hesitant to make big moves right now because of the market uncertainty. The US dollar also just had its worst weekly performance since 2022. Meanwhile, investors are playing it safe and rapidly buying bonds, which pushed the 10-year Treasury yield down to around 4.28%. While some investors are seeing the current market dip as a buying opportunity, Daniel Von Ahlen from GlobalData TS Lombard says otherwise. He believes the risks of a recession are being seriously underestimated. Even though Trump's recent tariff halt gave markets a bit of a boost, Ahlen thinks that bounce will not last. In his view, this is not the time to scoop up stocks on the cheap, he is actually advising people to sell into rallies and avoid the usual buy-the-dip strategy. Ahlen suggests getting a bit more cautious and selective. Instead of jumping into the whole market, he recommends focusing on defensive sectors, like utilities, consumer staples, and healthcare, that tend to hold up better in downturns. The market uncertainty is reflected in ETFs as well, which are often considered wiser investment options due to active management strategies and lower risk compared to individual investing. For example, the Guru ETF is down 8.30% year-to-date as of April 18. However, over the last 12 months, the fund has posted share price returns of 13.38%. Similarly, five-year share returns stand at an impressive 51.57%. GURU gives retail investors a way to tap into the top stock picks of major hedge funds at a relatively low 0.75% expense ratio. It offers a more affordable and flexible way to try and beat the broader market using expert insights. A close-up of a colorful high-end graphics card being plugged in to a gaming computer. For this article, we looked up the GURU ETF, which had 82 holdings as of April 18. Next, we manually searched for the average upside potential of each stock and selected 11 stocks with the highest values. The list below is ranked in ascending order of the upside potential as of April 18. We have also mentioned the hedge fund sentiment as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 223 Average Upside Potential: 68.36% NVIDIA Corporation (NASDAQ:NVDA) is one of the top AI, semiconductor, and computer graphics companies in the world. It ranks 10th on our list of the best Guru stocks. On April 17, Stifel analysts maintained a Buy rating on NVDA with a price target of $180. The company is taking a $5.5 billion inventory hit after the US implemented new export controls requiring special licenses to sell specific chips to China, including Hong Kong and Macau. However, analysts think NVIDIA Corporation (NASDAQ:NVDA)'s long-term growth story remains strong despite the near-term challenges. On April 14, NVIDIA Corporation (NASDAQ:NVDA) announced the production shift of its AI supercomputers to the US. The company plans to invest up to $500 billion over the next four years. The move follows sharp tariffs on imports from Taiwan and China, where Nvidia currently manufactures most of its chips. New factories are being built in Texas with Foxconn and Wistron, aiming for mass production in 12 to 15 months. Nvidia will also use its tech to create digital factory models and automate processes. According to Insider Monkey's fourth quarter database, 223 hedge funds were bullish on NVIDIA Corporation (NASDAQ:NVDA), up from 193 funds in the prior quarter. Ken Fisher's was a prominent stakeholder of the company, with 98.3 million shares valued at $13.20 billion. Overall, NVDA ranks 10th among the 11 Best Guru Stocks to Buy According to Wall Street Analysts. While we acknowledge the potential of NVDA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NVDA but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23-04-2025
- Business
- Yahoo
Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of . In this article, we are going to take a look at where NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over President Trump's tariffs earlier this month, but the rollercoaster is not over just yet. All three major indexes closed last week in the red, with the Dow and NASDAQ both dipping over 2%, and the broader market down more than 1%. Even though markets remain closed on April 18 for Good Friday, the general consensus is that the worst of the trade war headlines might be dying down. Marko Papic, chief strategist of geomacro strategy at BCA Research, remains cautiously optimistic, noting that while the idea of President Trump striking 90 trade deals in 90 days sounds ambitious, they will likely be small, symbolic wins that still help calm markets. That said, volatility is expected to continue, and Papic predicts the broader market could dip again before bouncing back, potentially giving investors a buying opportunity. Investors are deep in earnings season right now, and some of Wall Street's biggest banks have reported solid first-quarter results. A big part of their success came from their trading desks, which cashed in on the recent market volatility, especially in equities. However, despite strong numbers on paper, bank CEOs remain cautious and are hesitant to make big moves right now because of the market uncertainty. The US dollar also just had its worst weekly performance since 2022. Meanwhile, investors are playing it safe and rapidly buying bonds, which pushed the 10-year Treasury yield down to around 4.28%. While some investors are seeing the current market dip as a buying opportunity, Daniel Von Ahlen from GlobalData TS Lombard says otherwise. He believes the risks of a recession are being seriously underestimated. Even though Trump's recent tariff halt gave markets a bit of a boost, Ahlen thinks that bounce will not last. In his view, this is not the time to scoop up stocks on the cheap, he is actually advising people to sell into rallies and avoid the usual buy-the-dip strategy. Ahlen suggests getting a bit more cautious and selective. Instead of jumping into the whole market, he recommends focusing on defensive sectors, like utilities, consumer staples, and healthcare, that tend to hold up better in downturns. The market uncertainty is reflected in ETFs as well, which are often considered wiser investment options due to active management strategies and lower risk compared to individual investing. For example, the Guru ETF is down 8.30% year-to-date as of April 18. However, over the last 12 months, the fund has posted share price returns of 13.38%. Similarly, five-year share returns stand at an impressive 51.57%. GURU gives retail investors a way to tap into the top stock picks of major hedge funds at a relatively low 0.75% expense ratio. It offers a more affordable and flexible way to try and beat the broader market using expert insights. So, let's take a look at the best Guru stocks to buy. A scientist in a lab coat standing in a research lab examining biopharmaceuticals. For this article, we looked up the GURU ETF, which had 82 holdings as of April 18. Next, we manually searched for the average upside potential of each stock and selected 11 stocks with the highest values. The list below is ranked in ascending order of the upside potential as of April 18. We have also mentioned the hedge fund sentiment as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 36 Average Upside Potential: 166.09% NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a late-stage biotech company working on treatments for metabolic diseases. The company is developing obicetrapib, a pill aimed at lowering bad cholesterol and potentially treating Alzheimer's, with clinical trials currently in progress. It is one of the best Guru stocks to buy, ranking 2nd on our list. On February 27, Scotiabank analyst George Farmer maintained a Sector Outperform rating on NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) with a price target of $52, up from $47. The company's lead drug, obicetrapib, shows strong results in lowering bad cholesterol. The analyst observed that with $834 million in cash, extended patent protection to 2043, and regulatory filings expected in late 2025, the company is well-positioned for growth and potential acquisition. By the end of 2024, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)'s cash and marketable securities had grown to $834.2 million, up from $340.5 million in 2023. This increase came from public equity offerings, hitting a clinical milestone, and exercising warrants and options, although some of the cash went into R&D and higher administrative expenses. The company earned $45.6 million in revenue during 2024, a big leap from $14.1 million in 2023, mostly due to reaching a clinical milestone and receiving reimbursement for development costs. NewAmsterdam reported a net loss of $241.6 million for 2024, up from $176.9 million last year, mainly due to non-cash losses linked to changes in the value of their derivative liabilities. According to Insider Monkey's fourth quarter database, 36 hedge funds were bullish on NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), compared to 29 funds in the preceding quarter. Overall, NAMS ranks 2nd among the 11 Best Guru Stocks to Buy According to Wall Street Analysts. While we acknowledge the potential of NAMS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NAMS but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of . In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over President Trump's tariffs earlier this month, but the rollercoaster is not over just yet. All three major indexes closed last week in the red, with the Dow and NASDAQ both dipping over 2%, and the broader market down more than 1%. Even though markets remain closed on April 18 for Good Friday, the general consensus is that the worst of the trade war headlines might be dying down. Marko Papic, chief strategist of geomacro strategy at BCA Research, remains cautiously optimistic, noting that while the idea of President Trump striking 90 trade deals in 90 days sounds ambitious, they will likely be small, symbolic wins that still help calm markets. That said, volatility is expected to continue, and Papic predicts the broader market could dip again before bouncing back, potentially giving investors a buying opportunity. Investors are deep in earnings season right now, and some of Wall Street's biggest banks have reported solid first-quarter results. A big part of their success came from their trading desks, which cashed in on the recent market volatility, especially in equities. However, despite strong numbers on paper, bank CEOs remain cautious and are hesitant to make big moves right now because of the market uncertainty. The US dollar also just had its worst weekly performance since 2022. Meanwhile, investors are playing it safe and rapidly buying bonds, which pushed the 10-year Treasury yield down to around 4.28%. While some investors are seeing the current market dip as a buying opportunity, Daniel Von Ahlen from GlobalData TS Lombard says otherwise. He believes the risks of a recession are being seriously underestimated. Even though Trump's recent tariff halt gave markets a bit of a boost, Ahlen thinks that bounce will not last. In his view, this is not the time to scoop up stocks on the cheap, he is actually advising people to sell into rallies and avoid the usual buy-the-dip strategy. Ahlen suggests getting a bit more cautious and selective. Instead of jumping into the whole market, he recommends focusing on defensive sectors, like utilities, consumer staples, and healthcare, that tend to hold up better in downturns. The market uncertainty is reflected in ETFs as well, which are often considered wiser investment options due to active management strategies and lower risk compared to individual investing. For example, the Guru ETF is down 8.30% year-to-date as of April 18. However, over the last 12 months, the fund has posted share price returns of 13.38%. Similarly, five-year share returns stand at an impressive 51.57%. GURU gives retail investors a way to tap into the top stock picks of major hedge funds at a relatively low 0.75% expense ratio. It offers a more affordable and flexible way to try and beat the broader market using expert insights. So, let's take a look at the best Guru stocks to buy. A pharmacist in a white coat with a range of drugs on shelves behind her. For this article, we looked up the GURU ETF, which had 82 holdings as of April 18. Next, we manually searched for the average upside potential of each stock and selected 11 stocks with the highest values. The list below is ranked in ascending order of the upside potential as of April 18. We have also mentioned the hedge fund sentiment as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 41 Average Upside Potential: 213.78% Biohaven Ltd. (NYSE:BHVN) is a Connecticut-based biotech company, developing treatments for neuroscience, immunology, and cancer. The company is working on late-stage candidates for epilepsy, depression, migraines, spinal muscular atrophy, obesity, and neurodegenerative diseases like Alzheimer's and Parkinson's. BHVN ranks 1st on our list of the best Guru stocks to buy. On March 7, Piper Sandler maintained an Overweight rating on Biohaven Ltd. (NYSE:BHVN) with a $76 price target. The investment firm remains confident in Biohaven, highlighting the company's solid R&D pipeline, especially BHV-1300, which showed strong IgG-lowering results with a clean safety profile in early trials. With several milestones expected in 2025, analysts see plenty of room for growth and believe the stock is slightly undervalued right now. In Q4 2024, Biohaven Ltd. (NYSE:BHVN)'s R&D spending increased to $167.5 million from $134.8 million in the prior-year quarter. This reflects the company's growing pipeline, with more advanced clinical and preclinical trials underway. However, non-cash share-based compensation fell by $2 million since no new equity awards were granted in Q4 2024. Biohaven posted a net loss of $186.8 million for the fourth quarter, up from a $144.8 million loss in the same period last year. According to Insider Monkey's fourth quarter database, 41 hedge funds held long positions in Biohaven Ltd. (NYSE:BHVN), compared to 42 funds in the preceding quarter. Overall, BHVN ranks 1st among the 11 Best Guru Stocks to Buy According to Wall Street Analysts. While we acknowledge the potential of BHVN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BHVN but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23-04-2025
- Business
- Yahoo
Is Impinj, Inc. (PI) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of . In this article, we are going to take a look at where Impinj, Inc. (NASDAQ:PI) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over President Trump's tariffs earlier this month, but the rollercoaster is not over just yet. All three major indexes closed last week in the red, with the Dow and NASDAQ both dipping over 2%, and the broader market down more than 1%. Even though markets remain closed on April 18 for Good Friday, the general consensus is that the worst of the trade war headlines might be dying down. Marko Papic, chief strategist of geomacro strategy at BCA Research, remains cautiously optimistic, noting that while the idea of President Trump striking 90 trade deals in 90 days sounds ambitious, they will likely be small, symbolic wins that still help calm markets. That said, volatility is expected to continue, and Papic predicts the broader market could dip again before bouncing back, potentially giving investors a buying opportunity. Investors are deep in earnings season right now, and some of Wall Street's biggest banks have reported solid first-quarter results. A big part of their success came from their trading desks, which cashed in on the recent market volatility, especially in equities. However, despite strong numbers on paper, bank CEOs remain cautious and are hesitant to make big moves right now because of the market uncertainty. The US dollar also just had its worst weekly performance since 2022. Meanwhile, investors are playing it safe and rapidly buying bonds, which pushed the 10-year Treasury yield down to around 4.28%. While some investors are seeing the current market dip as a buying opportunity, Daniel Von Ahlen from GlobalData TS Lombard says otherwise. He believes the risks of a recession are being seriously underestimated. Even though Trump's recent tariff halt gave markets a bit of a boost, Ahlen thinks that bounce will not last. In his view, this is not the time to scoop up stocks on the cheap, he is actually advising people to sell into rallies and avoid the usual buy-the-dip strategy. Ahlen suggests getting a bit more cautious and selective. Instead of jumping into the whole market, he recommends focusing on defensive sectors, like utilities, consumer staples, and healthcare, that tend to hold up better in downturns. The market uncertainty is reflected in ETFs as well, which are often considered wiser investment options due to active management strategies and lower risk compared to individual investing. For example, the Guru ETF is down 8.30% year-to-date as of April 18. However, over the last 12 months, the fund has posted share price returns of 13.38%. Similarly, five-year share returns stand at an impressive 51.57%. GURU gives retail investors a way to tap into the top stock picks of major hedge funds at a relatively low 0.75% expense ratio. It offers a more affordable and flexible way to try and beat the broader market using expert insights. So, let's take a look at the best Guru stocks to buy. A close-up of a computer engineer working on the code for a cloud connectivity platform. For this article, we looked up the GURU ETF, which had 82 holdings as of April 18. Next, we manually searched for the average upside potential of each stock and selected 11 stocks with the highest values. The list below is ranked in ascending order of the upside potential as of April 18. We have also mentioned the hedge fund sentiment as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 37 Average Upside Potential: 109.79% Impinj, Inc. (NASDAQ:PI) offers a cloud connectivity platform worldwide. It connects everyday items, like clothes, car parts, and packages, to the internet using RAIN RFID technology. This allows businesses and consumers to access real-time information about these items, helping them improve efficiency, make smarter decisions, and unlock new possibilities through the Internet of Things. PI is one of the best Guru stocks to monitor. On March 19, Piper Sandler reaffirmed an Overweight rating on Impinj, Inc. (NASDAQ:PI) with a price target of $140. Analysts remain confident in the company's growth potential despite a short-term slowdown tied to one logistics customer. Management is optimistic, especially about RFID opportunities in the grocery sector. With strong margins and steady revenue growth, the company is seen as well-positioned to expand. In 2024, Impinj, Inc. (NASDAQ:PI) resolved a patent dispute and rolled out some new products. The company brought in $91.6 million in revenue and maintained a 50.5% GAAP gross margin and 53.1% on a non-GAAP basis during Q4 2024. Although it reported a GAAP net loss of $2.7 million, non-GAAP numbers told a more positive story with $14.5 million in net income and $15 million in adjusted EBITDA. According to Insider Monkey's fourth quarter database, 37 hedge funds were bullish on Impinj, Inc. (NASDAQ:PI), compared to 22 funds in the preceding quarter. Daniel Patrick Gibson's Sylebra Capital Management was the leading stakeholder of the company, with 2.12 million shares valued at $309.2 million. Overall, PI ranks 6th among the 11 Best Guru Stocks to Buy According to Wall Street Analysts. While we acknowledge the potential of PI as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than PI but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of . In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over President Trump's tariffs earlier this month, but the rollercoaster is not over just yet. All three major indexes closed last week in the red, with the Dow and NASDAQ both dipping over 2%, and the broader market down more than 1%. Even though markets remain closed on April 18 for Good Friday, the general consensus is that the worst of the trade war headlines might be dying down. Marko Papic, chief strategist of geomacro strategy at BCA Research, remains cautiously optimistic, noting that while the idea of President Trump striking 90 trade deals in 90 days sounds ambitious, they will likely be small, symbolic wins that still help calm markets. That said, volatility is expected to continue, and Papic predicts the broader market could dip again before bouncing back, potentially giving investors a buying opportunity. Investors are deep in earnings season right now, and some of Wall Street's biggest banks have reported solid first-quarter results. A big part of their success came from their trading desks, which cashed in on the recent market volatility, especially in equities. However, despite strong numbers on paper, bank CEOs remain cautious and are hesitant to make big moves right now because of the market uncertainty. The US dollar also just had its worst weekly performance since 2022. Meanwhile, investors are playing it safe and rapidly buying bonds, which pushed the 10-year Treasury yield down to around 4.28%. While some investors are seeing the current market dip as a buying opportunity, Daniel Von Ahlen from GlobalData TS Lombard says otherwise. He believes the risks of a recession are being seriously underestimated. Even though Trump's recent tariff halt gave markets a bit of a boost, Ahlen thinks that bounce will not last. In his view, this is not the time to scoop up stocks on the cheap, he is actually advising people to sell into rallies and avoid the usual buy-the-dip strategy. Ahlen suggests getting a bit more cautious and selective. Instead of jumping into the whole market, he recommends focusing on defensive sectors, like utilities, consumer staples, and healthcare, that tend to hold up better in downturns. The market uncertainty is reflected in ETFs as well, which are often considered wiser investment options due to active management strategies and lower risk compared to individual investing. For example, the Guru ETF is down 8.30% year-to-date as of April 18. However, over the last 12 months, the fund has posted share price returns of 13.38%. Similarly, five-year share returns stand at an impressive 51.57%. GURU gives retail investors a way to tap into the top stock picks of major hedge funds at a relatively low 0.75% expense ratio. It offers a more affordable and flexible way to try and beat the broader market using expert insights. So, let's take a look at the best Guru stocks to buy. A biomedical scientist in a lab coat conducting research on biopharmaceutical compounds. For this article, we looked up the GURU ETF, which had 82 holdings as of April 18. Next, we manually searched for the average upside potential of each stock and selected 11 stocks with the highest values. The list below is ranked in ascending order of the upside potential as of April 18. We have also mentioned the hedge fund sentiment as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 44 Average Upside Potential: 132.43% Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a biopharmaceutical company that develops treatments for diseases with limited options. The company's product pipeline is focused on geographic atrophy and rare kidney and transplant-related conditions. APLS is one of the best Guru stocks to invest in. On March 3, Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) but trimmed the price target from $78 to $75. Despite expecting a slowdown in early 2025 due to Medicare paperwork, bad weather, and more product samples being used, the company sees strong growth ahead, supported by a 97% revenue boost over the past year and a healthy financial cushion. Apellis is especially optimistic about Syfovre, noting its flexible dosing schedule and strong backing from major insurers like Aetna. Syfovre could help Apellis grow its share in a competitive market that it has tapped into about 10% for now. In the fourth quarter of 2024, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) earned $212.5 million in total revenue, driven by strong US sales of Syfovre and Empaveli, along with earnings from its Sobi partnership. The company also made progress in cutting its losses, with net losses dropping to $36.4 million for the quarter and $197.9 million for the year. With over $411 million in cash, Apellis is confident that its current financial position and product revenue will carry it through to profitability. According to Insider Monkey's fourth quarter database, 44 hedge funds were long Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), compared to 35 funds in the earlier quarter. Kurt Von Emster's VenBio Select Advisor was the largest stakeholder of the company, with 12.2 million shares valued at $390 million. Overall, APLS ranks 4th among the 11 Best Guru Stocks to Buy According to Wall Street Analysts. While we acknowledge the potential of APLS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than APLS but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
